Sarepta Therapeutics Revenue 2006-2021 | SRPT

Sarepta Therapeutics annual/quarterly revenue history and growth rate from 2006 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Sarepta Therapeutics revenue for the quarter ending June 30, 2021 was $0.164B, a 19.46% increase year-over-year.
  • Sarepta Therapeutics revenue for the twelve months ending June 30, 2021 was $0.600B, a 33.29% increase year-over-year.
  • Sarepta Therapeutics annual revenue for 2020 was $0.54B, a 41.82% increase from 2019.
  • Sarepta Therapeutics annual revenue for 2019 was $0.381B, a 26.51% increase from 2018.
  • Sarepta Therapeutics annual revenue for 2018 was $0.301B, a 94.74% increase from 2017.
Sarepta Therapeutics Annual Revenue
(Millions of US $)
2020 $540
2019 $381
2018 $301
2017 $155
2016 $5
2015 $1
2014 $10
2013 $14
2012 $37
2011 $47
2010 $29
2009 $18
2008 $21
2007 $11
2006 $0
2005 $5
Sarepta Therapeutics Quarterly Revenue
(Millions of US $)
2021-06-30 $164
2021-03-31 $147
2020-12-31 $145
2020-09-30 $144
2020-06-30 $137
2020-03-31 $114
2019-12-31 $100
2019-09-30 $99
2019-06-30 $95
2019-03-31 $87
2018-12-31 $84
2018-09-30 $78
2018-06-30 $74
2018-03-31 $65
2017-12-31 $57
2017-09-30 $46
2017-06-30 $35
2017-03-31 $16
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31 $0
2014-09-30 $1
2014-06-30 $3
2014-03-31 $6
2013-12-31 $3
2013-09-30 $4
2013-06-30 $3
2013-03-31 $4
2012-12-31 $7
2012-09-30 $8
2012-06-30 $11
2012-03-31 $11
2011-12-31 $14
2011-09-30 $8
2011-06-30 $12
2011-03-31 $14
2010-12-31 $16
2010-09-30 $9
2010-06-30 $4
2010-03-31 $1
2009-12-31 $5
2009-09-30 $6
2009-06-30 $3
2009-03-31 $3
2008-12-31 $5
2008-09-30 $5
2008-06-30 $5
2008-03-31 $6
2007-12-31 $5
2007-09-30 $3
2007-06-30 $2
2007-03-31 $1
2006-12-31 $0
2006-09-30 $0
2006-06-30 $0
2006-03-31 $0
2005-12-31 $1
2005-09-30 $3
2005-06-30 $0
2005-03-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $6.722B $0.540B
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma, Inc., is headquartered in Bothell, Washington.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00